Advancing Regulatory Science for Medical Countermeasure by Institute of Medicine, Board on Health Sciences Policy,

By Institute of Medicine, Board on Health Sciences Policy, Forum on Medical and Public Health Preparedness for Catastrophic Events, Development, and Translation Forum on Drug Discovery, Anne B. Claiborne, Bruce M. Altevogt, Theresa Wizemann

Even if the us has secure and powerful scientific countermeasures--such as vaccines, medicinal drugs, and diagnostic tools--available to be used in the course of a catastrophe can suggest the adaptation among lifestyles and loss of life for plenty of americans. The nutrition and Drug management (FDA) and the medical neighborhood at huge may benefit from enhanced clinical instruments and analytic innovations to adopt the complicated medical review and choice making had to make crucial scientific countermeasures to be had. on the request of FDA, the Institute of medication (IOM) held a workshop to envision the way to increase the improvement, assessment, approval, and legislation of clinical countermeasures.

During public well-being emergencies reminiscent of influenza or chemical, organic, radiological/nuclear (CBRN) assaults, secure and powerful vaccines, remedies, and different scientific countermeasures are necessary to keeping nationwide protection and the health of the general public. Advancing Regulatory technological know-how for scientific Countermeasure Development examines present clinical countermeasures, and investigates the way forward for examine and improvement during this sector. Convened on March 29-30, 2011, this workshop pointed out regulatory technological know-how instruments and techniques which are to be had or lower than improvement, in addition to significant gaps in presently to be had regulatory technology instruments.

Advancing Regulatory technological know-how for clinical Countermeasure Development is a beneficial source for federal enterprises together with the nutrition and Drug management (FDA), the dep. of future health and Human companies (HHS), the dep. of safeguard (DoD), in addition to overall healthiness execs, and private and non-private health and wellbeing businesses.

Show description

Read Online or Download Advancing Regulatory Science for Medical Countermeasure Development: Workshop Summary PDF

Similar health policy books

Health Financing for Poor People: Resource Mobilization and Risk Sharing

So much neighborhood financing schemes have advanced within the context of serious fiscal constraints, political instability, and absence of excellent governance. often govt taxation means is susceptible, formal mechanisms of social safety for susceptible populations absent, and executive oversight of the casual overall healthiness zone missing.

Repositioning Nutrition as Central to Development: A Strategy for Large Scale Action (Directions in Development)

Continual malnutrition is contributing not just to common failure to satisfy the 1st MDG—to halve poverty and hunger—but to satisfy different targets in maternal and baby health and wellbeing, HIV/AIDS, schooling, and gender fairness. the alternative is now among carrying on with to fail, or to eventually make nutrients valuable to improvement.

Health Policy and Advanced Practice Nursing: Impact and Implications

This view of healthiness coverage from the point of view of APRN perform is a decision to motion for complex perform nurses to benefit concerning the influence and implications of present projects in well-being coverage. this data will support them in deciding on how they outline and create confident swap for his or her sufferers and feature an impression on neighborhood, nationwide, and international wellbeing and fitness.

The economics of genomic medicine : workshop summary

Monetary versions are usually used to expect the prices and merits of latest overall healthiness care applied sciences, regulations, and laws. fiscal experiences even have been used to check even more particular concerns, corresponding to evaluating the results and cost-effectiveness of 2 diversified drugs for a similar situation.

Extra info for Advancing Regulatory Science for Medical Countermeasure Development: Workshop Summary

Sample text

To aid benefit-risk decisions, Rose suggested, reviewers of MCMs ought to have the requisite security clearances to be allowed to read the associated confidential population threat assessments. In later discussion about safety assessment, Richard Forshee of the Office of Biostatistics and Epidemiology at CBER, mentioned current agency efforts to develop risk assessment models to support regulatory decision making. These probabilistic quantitative computer simulation models can help explore how different regulatory science options could ultimately have an impact on public health, and thereby improve decision making.

Elizabeth Leffel, director of nonclinical sciences at PharmAthene, said that a strategic plan for utilizing the Animal Rule is needed, starting with finalizing the current draft guidance. Rose noted in his remarks that the Animal Rule is the primary obstacle to demonstrating substantial effectiveness of a product. He pointed out that many threat agents are not testable in clinical scenarios (one could not conduct a randomized trial of an Ebola treatment, for example), yet the Animal Rule has never been the basis for approval of a new chemical entity.

Animal Model Case Study and Discussion Drusilla Burns from the Office of Vaccines Research and Review in FDA’s CBER offered as a case study the pathway to licensure for anthrax vaccines. Animal models were developed, she said, that were thought to be appropriately reflective of human disease. It was demonstrated that an immune marker, anthrax toxin neutralization antibodies, correlated with protection in the animals, and the protective level of antibody was 1 A participant from FDA clarified the status of the draft Animal Rule guidance.

Download PDF sample

Rated 4.19 of 5 – based on 41 votes